Q4 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Neuphoria Therapeutics(NEUP) the Revenue is 1.138 M (+8746%), Beat estimate;the EPS is -0.95 (+82.88%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B8746.43%
0.00B100.00%
+0.00B8,646.43%
EBIT
TBA--
-0.01B34.22%
----
EPSMiss expectations
-0.9582.88%
-0.5689.91%
-0.39007.03%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf